Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epirubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL12349863 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL1501770 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21184881 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14227487 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL24421866 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14562311 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22403027 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21914951 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22291815 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2768 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722240-A1 | COMBINATION OF ANTIBODIES, OR ANTIGEN-BINDING FRAGMENTS THEREOF, FOR THE TREATMENT OF CANCERS AND COMPOSITIONS THEREOF | Xenothera (FR) | 2026-04-08 | — | — | EP | claimed |
| US-20260070946-A1 | TYR PEPTIDE COMPOSITIONS AND METHODS FOR USE | UNIV MIAMI (US) | 2026-03-12 | — | — | US | claimed |
| WO-2025151135-A1 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025073856-A1 | COMBINATION OF ANTIBODIES, OR ANTIGEN-BINDING FRAGMENTS THEREOF, FOR THE TREATMENT OF CANCERS | XENOTHERA (FR) | 2025-04-10 | — | — | WO | claimed |
| CN-112368019-B | Methods of treating cancer and enhancing the efficacy of T cell redirecting therapeutics | 詹森生物科技公司 | 2025-03-18 | — | — | CN | claimed |
| US-20250025504-A1 | TREATMENT OF B CELL MALIGNANCIES | ADICET THERAPEUTICS, INC. | 2025-01-23 | — | — | US | claimed |
| WO-2024243058-A1 | TREATMENT OF CANCER WITH NK CELLS AND BENDAMUSTINE | ARTIVA BIOTHERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | claimed |
| EP-4440582-A1 | TREATMENT OF B CELL MALIGNANCIES | Adicet Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| US-20240301083-A1 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS | Stichting Amsterdam UMC (NL) | 2024-09-12 | — | — | US | claimed |
| EP-4427805-A2 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | Genentech, Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| US-20090298786-A1 | METHODS OF TREATING VIRAL INFECTIONS WITH ANTHRACYCLINE ANTIBIOTICS | INSTYTUT BIOTECHNOLOGII I ANTYBIOTYKOW (PL) | 2009-12-03 | — | — | US | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070275911-A1 | Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-11-29 | — | — | US | claimed |
| US-20070015949-A1 | Selective destruction of cancerous cellular tissue | KAISER DANIEL E | 2007-01-18 | — | — | US | claimed |
| EP-1015448-A4 | ANTI-CANCER DRUG ALDEHYDE CONJUGATE DRUGS WITH ENHANCED CYTOTOXICITY: COMPOUNDS, COMPOSITIONS AND METHODS | UNIV TECHNOLOGY CORP (US) | 2001-02-07 | — | — | EP | claimed |
| EP-1015448-A1 | ANTI-CANCER DRUG ALDEHYDE CONJUGATE DRUGS WITH ENHANCED CYTOTOXICITY: COMPOUNDS, COMPOSITIONS AND METHODS | University Technology Corporation (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998046598-A1 | ANTI-CANCER DRUG ALDEHYDE CONJUGATE DRUGS WITH ENHANCED CYTOTOXICITY: COMPOUNDS, COMPOSITIONS AND METHODS | UNIVERSITY TECHNOLOGY CORPORATION (US) | 1998-10-22 | — | — | WO | claimed |
| JP-H08502519-A | — | — | 1996-03-19 | — | — | JP | claimed |
| EP-0649312-A1 | ANTHRACYCLINE CONJUGATES, THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 1995-04-26 | — | — | EP | claimed |
| WO-1994026311-A1 | ANTHRACYCLINE CONJUGATES, THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA S.P.A. (IT) | 1994-11-24 | — | — | WO | claimed |